Zilebesiran for Uncontrolled Hypertension and Heart Risk
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 11,000 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
This trial is looking for adults with high blood pressure that is not well controlled and have either a history of heart disease or are at high risk for heart disease. Participants will receive either the study drug, zilebesiran, or a placebo to see if it lowers the risk of serious heart-related events.
You may be able to join if
- I am 18 years or older with heart disease
- I am 55 years or older with high risk for heart disease
- I have heart disease or high risk for heart disease
- I have high blood pressure that is treated with stable medicine
You may not be able to join if
- I have a history of secondary hypertension
- I have symptoms of orthostatic hypotension
- My liver enzyme levels are very high
- My bilirubin levels are too high
- My blood clotting levels are too high
- My potassium levels are too high
- My kidney function is very low
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
Loading trial locations…